

and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene3 β ,17 β -diol] and androst-5-ene-3 β ,17 β -diol.

REMARKS

Claims 2-4 and 39-104 are presently pending this application. By this Second Preliminary Amendment, applicant has amended the specification and claims 63-68, 78-83, 90-92 and 96-98 to correct a typographical errors contained therein. Applicant maintains that the above amendment raises no issue of new matter.

In light of the foregoing, it is respectfully submitted that this application is now in condition to be allowed and the early issuance of a Notice of Allowance is respectfully solicited.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on May 16, 2000:

Charles C. Achkar

Name of applicant, assignee or
Registered Representative

Charles C. Achkar

Signature
May 16, 2000

Date of Signature

WOG/CCA:lac

Respectfully submitted,

Charles C. Achkar

Charles C. Achkar

Registration No.: 43,311

OSTROLENK, FABER, GERB & SOFFEN, LLP

1180 Avenue of the Americas

New York, New York 10036-8403

Telephone: (212) 382-0700